<DOC>
	<DOCNO>NCT02444390</DOCNO>
	<brief_summary>This prospective biomarker study show p4EBP1 stain predicts clinical benefit treatment everolimus patient eligible everolimus+exemestane treatment . This trial aim evaluating drug activity . Everolimus exemestane prescribe within approve indication per usual practice part trial .</brief_summary>
	<brief_title>Molecular Alterations Associated With Resistance Endocrine Therapy Impacting Treatment With mTOR Inhibitor</brief_title>
	<detailed_description>Estrogen hormone receptor-positive metastatic breast cancer fail non steroidal aromatases inhibitor patient eligible everolimus+exemestane treatment</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Eligible everolimus+exemestane treatment require marketing authorisation condition 1 . Women ( men ) histologicallyproven ER+ and/or PR+ /HER2 metastatic breast adenocarcinoma locally advanced disease treat surgery and/or radiation therapy 2. postmenopausal woman 3. asymptomatic visceral disease 4. second line hormonotherapy metastatic locally advanced disease recurrence progression follow nonsteroidal aromatase inhibitor ( adjuvant metastatic setting ) Eligible biopsy 5 . Progressive disease endocrine therapy time inclusion 6 . Treatment everolimus exemestane yet start 7 . Patients metastasis biopsied , except bone metastases 8 . Measurable evaluable disease 9 . Age ≥ 18 year 10. WHO Performance Status 0/1 11 . Provision sign date , write informed consent prior protocol specific procedure , include biopsy 12 . Patient social insurance coverage 1 . Contraindications everolimus+exemestane treatment 2 . Previous treatment antimTOR therapy 3 . More 1 previous line chemotherapy metastatic set 4 . Life expectancy &lt; 3 month , 5 . Spinal cord compression and/or symptomatic progressive brain metastasis ( unless asymptomatic treat stable steroid least 30 day prior start study drug ) . 6 . Haematopoietic function organ impairment show follow criterion : Polynuclear neutrophils &lt; 1.5 x 109/L Platelets &lt; 100 x 109/L Haemoglobin &lt; 90 g/L ALAT/ASAT &gt; 2.5x ULN absence &gt; 5x ULN presence liver metastases bilirubin &gt; 1.5xULN creatinine clearance ≤50 mL/min ( measure calculate Cockroft Gault formula ) calcium phosphate &gt; ULN 7 . Abnormal coagulation medical situation contraindicate biopsy 8 . Bone metastases site biopsiable disease 9 . Any condition Investigator 's opinion make undesirable subject participate trial would jeopardize compliance protocol . 10 . Individuals deprive liberty place authority tutor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Failed non steroidal aromatases inhibitor</keyword>
	<keyword>Eligible everolimus+exemestane</keyword>
</DOC>